Alpha Tau Medical Ltd. DRTS
12.14 USD -1.24 (-9.27%)
As ofNov 16, 2026, 12:32 PM EST
12.04 Day range 14.41
3.43 52-week range 15.79
- YTD
- +145.25%
- 1 year
- +227.22%
News
benzinga.com Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients Alpha Tau Medical Ltd. (NASDAQ:DRTS) on Sunday reported positive interim results from its U.S. REGAIN trial evaluating Alpha DaRT therapy in patients with recurrent glioblastoma.
benzinga.com Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients Alpha Tau Medical reports a 100% objective response rate and strong safety in interim U.S. REGAIN glioblastoma trial data.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS)…
benzinga.com Why Take-Two Interactive Software Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.benzinga.com Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment…
globenewswire.com Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16 - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment…
globenewswire.com Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial JERUSALEM, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today…
benzinga.com This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded RSG, AAPL, MRCY, DK and DRTS, revising price targets, including AAPL to $425 and DRTS to $22.benzinga.com Piper Sandler Upgrades Alpha Tau Medical to Overweight, Raises Price Target to $22 Piper Sandler analyst Allison Bratzel upgrades Alpha Tau Medical (NASDAQ:DRTS) from Neutral to Overweight and raises the price target from $8 to $22.
benzinga.com Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026 Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdingsTA-125 tracks the 125 largest and most prominent companies on the TASEJERUSALEM, Oct. 29, 2026…
benzinga.com Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the signing of an MOU in Seoul, South Korea,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
benzinga.com Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration…
